Public Employees Retirement System of Ohio Makes New Investment in Insulet Corporation $PODD

Posted by George Bondi on Sep 5th, 2026

Public Employees Retirement System of Ohio acquired a new stake in Insulet Corporation (NASDAQ:PODD – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,855 shares of the medical instruments supplier’s stock, valued at approximately $3,023,000.

Other large investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its holdings in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet during the 4th quarter valued at about $26,000. DV Equities LLC purchased a new position in Insulet during the 4th quarter valued at about $28,000. Elyxium Wealth LLC acquired a new position in Insulet in the 4th quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in Insulet during the fourth quarter worth about $29,000.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. William Blair began coverage on shares of Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating on the stock. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Evercore set a $180.00 target price on shares of Insulet in a report on Monday, July 6th. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group dropped their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $195.40.

Get Our Latest Stock Analysis on PODD

Insulet Trading Down 2.1%

NASDAQ PODD opened at $147.48 on Friday. The firm’s fifty day moving average price is $154.45 and its 200 day moving average price is $177.72. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company has a market capitalization of $10.23 billion, a price-to-earnings ratio of 27.57, a price-to-earnings-growth ratio of 1.19 and a beta of 1.08.

Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same period in the previous year, the company earned $1.17 earnings per share. Insulet’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts expect that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insulet Company Profile

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.